DALLAS — In the SIENA trial, nearly three-quarters of patients with mild, persistent asthma had low sputum eosinophil levels and did not differ in their response to either mometasone or tiotropium when compared with placebo treatment.
“Based on prior work from our lab and others, we anticipated that perhaps 40% to 50% of patients with mild persistent asthma would have ‘low levels’ of eosinophils in their sputum. We were quite surprised to discover that nearly three-quarters (73%) of these patients were ‘eosinophil low,’” Stephen C. Lazarus, MD, professor of medicine, director of the fellowship program in pulmonary and critical care medicine and associate director of the University of California, San Francisco, American Lung Association Airways Clinical Research enter, wrote in an email to Healio Pulmonology. “It was less surprising, but very important, to discover that in 67% of these patients with mild persistent asthma and low levels of sputum eosinophils, the response to placebo was either as good as or better than the response to corticosteroid.”
No commercial support for this activity.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.